|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||3.0000 - 3.0850|
|52-week range||3.0000 - 3.0850|
|Beta (5Y monthly)||1.86|
|PE ratio (TTM)||25.42|
|Earnings date||26 Apr 2022 - 02 May 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
Shares of Opko Health (NASDAQ: OPK) were jumping 13.5% higher as of 12:31 p.m. ET on Tuesday. Opko also announced on Monday that it has acquired ModeX Therapeutics in an all-stock deal valued at $300 million. The acquisition of ModeX could be good for Opko over the long term.
This is Yvonne Briggs with LHA. Thank you all for joining today's call to discuss OPKO Health's financial results for the first quarter of 2022, as well as the recently announced ModeX Therapeutics acquisition.